Toll-like receptor 9 SNPs are susceptible to the development and progression of membranous glomerulonephritis: 27 years follow-up in Taiwan

References

• Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329:85–89
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Membranous nephropathy. J Nephrol. 2007;20:268–287
   PubMed Web of Science ®Google Scholar
• Murtas C, Ravani P, Ghiggeri GM. New insights into membranous glomerulo-nephritis: from bench to bedside. Nephrol Dial Transplant. 2011;26:2428–2430
   PubMedGoogle Scholar
• Beck LH Jr, Bonegio RG, Lambeau G. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21
   PubMed Web of Science ®Google Scholar
• Prunotto M, Carnevali ML, Candiano G. Autoimmunity in membranous nephron-pathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010;21:507–519
   PubMedGoogle Scholar
• Bruschi M, Carnevali ML, Murtas C. Direct characterization of target podocyte antigens and autoantibodies in human membranous glomerulonephritis: alpha-enolase and borderline antigens. J Prot. 2008;74:2008–2017
   Google Scholar
• Couser WG, Nangaku M. Cellular and molecular biology of membranous nephron apathy. J Nephrol. 2006;19:699–705
   PubMedGoogle Scholar
• Ronco P, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens. 2006;15:258–263
   PubMedGoogle Scholar
• Wehrmann M, Bohle A, Bogenschutz O, et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulointerstitial change. Clin Nephrol. 1989;31:67–76
   PubMed Web of Science ®Google Scholar
• Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006;69:1641–1648
   PubMed Web of Science ®Google Scholar
• Kodner C. Nephrotic syndrome in adults: diagnosis and management. Am Fam Physician. 2009;80:1129–1134
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Secondary membranous glomerulonephritis. Nephrol Dial Transplant. 1992;7:64–71
   PubMed Web of Science ®Google Scholar
• Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol. 2008;4:550–559
   PubMedGoogle Scholar
• Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157–165
   PubMed Web of Science ®Google Scholar
• Hsu CC, Hwang SJ, Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis. 2006;48:727–738
   PubMedGoogle Scholar
• Grassmann A, Gioberge S, Moeller S, et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20:2587–2593
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CJ. The Toll receptor family and microbial recognition. Trends Microbiol. 2008;8:452–456
   Google Scholar
• Diebold SS, Matoya M, Unger H, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature. 2003;424:324–328
   PubMed Web of Science ®Google Scholar
• Blackwell SE, Krieg AM. CpG-DNA induced monocyte IFN inducible protein 10 production is regulated by plasmacytoid DC derived IFN alpha. J Immunol. 2003;170:4061–4068
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Zeuner RA. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 2003;24:519–523
   PubMed Web of Science ®Google Scholar
• Shirali AC, Goldstein DR. Tracking the toll of kidney disease. J Am Soc Nephrol. 2008;19:1444–1450
   PubMed Web of Science ®Google Scholar
• Gluba A, Banach M, Hannam S, et al. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6:224–235
   PubMed Web of Science ®Google Scholar
• Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007;18:1721–1731
   PubMed Web of Science ®Google Scholar
• Papadimitraki ED, Tzardi M, Bertsias G, et al. Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus. 2009;18:831–835
   PubMed Web of Science ®Google Scholar
• Summers SA, Steinmetz OM, Ooi JD, et al. Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am J Pathol. 2010;177:2234–2244
   PubMedGoogle Scholar
• Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001;59:1983–1994
   PubMed Web of Science ®Google Scholar
• Chen CH, Shu KH, Wen MC, et al. Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy. Nephrol Dial Transplant. 2008;23:3166–3173
   PubMedGoogle Scholar
• Bantis C, Heering PJ, Aker S, et al. Tumor necrosis factor-alpha gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis. Am J Nephrol. 2006;26:12–15
   PubMedGoogle Scholar
• Stratta P, Bermond F, Guarrera S, et al. Interaction between gene polymorphisms of nitric oxide synthase and renin–angiotensin system in the progression of membranous glomerulonephritis. Nephrol Dial Transplant. 2004;19:587–595
   PubMedGoogle Scholar
• Xu CJ, Zhang WH, Pan HF, et al. Association study of a single nucleotide polymorphism in the exon 2 region of toll-like receptor 9 (TLR9) gene with susceptibility to systemic lupus erythematosus among Chinese. Mol Biol Rep. 2009;36:2245–2248
   PubMed Web of Science ®Google Scholar